Viking's oral weight loss drug ap­pears to have strong ef­fect in Phase 1 tri­al

SAN AN­TO­NIO — Viking Ther­a­peu­tics’ high­ly an­tic­i­pat­ed read­out of its oral an­ti-obe­si­ty pill showed a place­bo-ad­just­ed weight loss of 6.8% af­ter four weeks, stick­ing the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER